

METHODS OF USING SECONDARY LYMPHOID ORGAN CHEMOKINE TO MODULATE PHYSIOLOGICAL PROCESSES IN MAMMALS

Abstract of the Disclosure

5 The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors *in vivo*. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.

10

"Express Mail" mailing label number EV3299537US
Date of Deposit JAN. 13 2004
I hereby certify that this paper or fee is being de-
posited with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10 on
the date indicated above and is addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
ISABELL OGATA
(printed name)
Isabell Ogata
(signature)